The Board at its meeting held today has recommended Final Dividend (for the F.Y. 2025-26) of Rs. 10/- (100%) per equity share of face value of Rs. 10/- each to the shareholders for their ....
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.0 pts less than Nifty Microcap 250 and 4.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Corona Remedies' Board has recommended a final dividend of Rs. 10 per share (100% payout on face value of Rs. 10) for shareholders' approval at the ensuing AGM. The record date is June 19, 2026, and payment will be made by August 7, 2026. For the full year FY2026, standalone net profit rose to Rs. 184.85 crore from Rs. 149.05 crore in the prior year, driven by revenue of Rs. 1,403 crore vs Rs. 1,196 crore. The company listed on NSE/BSE in December 2025 via an IPO (offer for sale). Paid-up share capital stands at Rs. 61.16 crore (6.12 crore shares). Based on the IPO issue price of Rs. 1,062, the dividend yield is approximately 0.94%, well below the 3% threshold.
The dividend declaration signals financial health and cash generation, though the yield is low given the premium IPO listing price. As a newly listed company, this inaugural dividend as a public entity is positive for investor sentiment but is unlikely to materially move the stock given its small absolute payout.